文献速递流行病学与生物统计临床试验与 GCP

「有希望区」设计的系统综述

A systematic review of the "promising zone" design.
PubMed 文献 · Trials · 2020-12-04

该研究系统综述了「有希望区」设计的当前方法学与临床应用,检索共识别270条记录,纳入171篇文献(其中30项为试验)。15项已完成试验中7项增加了样本量;仅21项研究报告了考虑的最大样本量,中位增幅50%(IQR 35-100%)。

要点

  • 「有希望区」设计在全球范围有应用但数量较少。
  • 因样本量再估计方法学报告不足,识别此类试验困难。
  • 部分报告缺失关键期中分析细节,仅8篇提供有希望区范围。

核心结论

  • 「有希望区」设计正被用于全球范围内的试验,但数量较低。
  • 样本量再估计方法学报告不足导致识别此类试验困难。
  • 即使报告了方法学,部分关键期中分析细节仍缺失。

研究设计与样本

  • 系统综述,按预设检索策略检索数据库并实施滚雪球技术。
  • 共识别270条唯一记录,纳入171篇文献,其中30项为试验。

主要发现

  • 期中分析时间中位数为原目标样本量的60%(IQR 41-73%)。
  • 15项已完成试验中7项增加了样本量。
  • 仅21项研究报告了考虑的最大样本量,中位增幅50%(IQR 35-100%)。
  • 仅8篇文献提供了有希望区范围。

局限性

  • 因样本量再估计方法学报告不足,识别使用「有希望区」的试验困难。
  • 部分报告虽含方法学但缺失关键期中分析细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sample size calculations require assumptions regarding treatment response and variability. Incorrect assumptions can result in under- or overpowered trials, posing ethical concerns. Sample size re-estimation (SSR) methods investigate the validity of these assumptions and increase the sample size if necessary. The "promising zone" (Mehta and Pocock, Stat Med 30:3267-3284, 2011) concept is appealing to researchers for its design simplicity. However, it is still relatively new in the application and has been a source of controversy. OBJECTIVES: This research aims to synthesise current approaches and practical implementation of the promising zone design. METHODS: This systematic review comprehensively identifies the reporting of methodological research and of clinical trials using promising zone. Databases were searched according to a pre-specified search strategy, and pearl growing techniques implemented. RESULTS: The combined search methods resulted in 270 unique records identified; 171 were included in the review, of which 30 were trials. The median time to the interim analysis was 60% of the original target sample size (IQR 41-73%). Of the 15 completed trials, 7 increased their sample size. Only 21 studies reported the maximum sample size that would be considered, for which the median increase was 50% (IQR 35-100%). CONCLUSIONS: Promising zone is being implemented in a range of trials worldwide, albeit in low numbers. Identifying trials using promising zone was difficult due to the lack of reporting of SSR methodology. Even when SSR methodology was reported, some had key interim analysis details missing, and only eight papers provided promising zone ranges.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Edwards JM, Walters SJ, Kunz C, et al. A systematic review of the "promising zone" design. Trials. 2020. PMID: 33276810. doi:10.1186/s13063-020-04931-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。